{
  "id": "resp_0d60569d5f8a3b8d00693c816b7c048190a2efcda280f11cea",
  "object": "response",
  "created_at": 1765572971,
  "status": "completed",
  "background": false,
  "billing": {
    "payer": "developer"
  },
  "error": null,
  "incomplete_details": null,
  "instructions": null,
  "max_output_tokens": null,
  "max_tool_calls": null,
  "model": "gpt-5.2-2025-12-11",
  "output": [
    {
      "id": "rs_0d60569d5f8a3b8d00693c816bead4819098826b7b548aa5f0",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c81712bec81908a97e07ca7d0608e",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "CDK12/13 inhibitor SR-4835 triple-negative breast cancer"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c81739ba88190a00ed57d56539e5b",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c8175b528819088b5a732a8ddbe03",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "jRCT CDK12 breast cancer"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c8177ccd08190bdd44b34b498436b",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c818607e481908d95d6e6c70abb51",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c818819588190964787ce107e5207",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c818865048190bbf84960cd550bdd",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "find_in_page",
        "pattern": "PROTAC",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c818b0d1c81908e7c327d5aa2bd9e",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c818c5ec081908761555e1c451cd3",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c818e67f48190bf2b25df954f09c4",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c818f5d848190915c4a9ee53d68de",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c8190d9848190a6728f136e0d5e4c",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c81929a288190b54b093b8d4b3154",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "HQ461 clinical trial"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c81961f148190bfa0ed1a0f2f65b1",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c8196b9148190b5900d9f4e0421ba",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c8198833c8190a43f63d6b904751b",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c819ac0748190bcf21de5ab1250bc",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://clinicaltrials.gov/study/NCT06600789"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c819c282081908ec9b827ea6004bb",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c819d8e4881908235a4b55827eed6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c819f205c8190a20ffd8e369375e5",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c81a0770c819091f536199e5cb5f8",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "site:clinicaltrials.gov NCT06600789 locations"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c81a3dc988190b07de66cdc8e9dea",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c81a589d08190bfc696ab3d4a4c04",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "clinicaltrials.gov api v2 studies NCT06600789"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c81a99aec8190a6e727f4fc5b8604",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c81aa133c8190a6c13adc06b750a6",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "https://clinicaltrials.gov/api/v2/studies/NCT06600789"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c81ace58081908b49546d66db2d48",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c81aef3f881909505bb89e9a6a9bb",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "open_page",
        "url": "https://cdek.pharmacy.purdue.edu/trial/NCT06600789/"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c81b0c5e881908fd92b9d87489088",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c81b7cff48190a12354234d21b03a",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "api/legacy/public-xml/NCT06600789?full=true"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c81bbd2e48190b633fe66cbda6211",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "ws_0d60569d5f8a3b8d00693c81bd71e48190bcbb7c15344e0f35",
      "type": "web_search_call",
      "status": "completed",
      "action": {
        "type": "search",
        "query": "ct2/show/NCT06600789?displayxml=true"
      }
    },
    {
      "id": "rs_0d60569d5f8a3b8d00693c81c3780c8190861bb5d42cf1ea03",
      "type": "reasoning",
      "summary": []
    },
    {
      "id": "msg_0d60569d5f8a3b8d00693c81e519e48190aa255ff2fae3af28",
      "type": "message",
      "status": "completed",
      "content": [
        {
          "type": "output_text",
          "annotations": [
            {
              "type": "url_citation",
              "end_index": 407,
              "start_index": 337,
              "title": "Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/31668947/"
            },
            {
              "type": "url_citation",
              "end_index": 757,
              "start_index": 687,
              "title": "Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
            },
            {
              "type": "url_citation",
              "end_index": 909,
              "start_index": 839,
              "title": "Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
            },
            {
              "type": "url_citation",
              "end_index": 1060,
              "start_index": 990,
              "title": "Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/35938508/"
            },
            {
              "type": "url_citation",
              "end_index": 1476,
              "start_index": 1406,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 1694,
              "start_index": 1624,
              "title": "Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/34864331/"
            },
            {
              "type": "url_citation",
              "end_index": 2038,
              "start_index": 1968,
              "title": "Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32804079/"
            },
            {
              "type": "url_citation",
              "end_index": 2221,
              "start_index": 2151,
              "title": "Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32804079/"
            },
            {
              "type": "url_citation",
              "end_index": 2405,
              "start_index": 2335,
              "title": "Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/32804079/"
            },
            {
              "type": "url_citation",
              "end_index": 2751,
              "start_index": 2681,
              "title": "Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/39090085/"
            },
            {
              "type": "url_citation",
              "end_index": 2968,
              "start_index": 2898,
              "title": "Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex - PubMed",
              "url": "https://pubmed.ncbi.nlm.nih.gov/39090085/"
            },
            {
              "type": "url_citation",
              "end_index": 3318,
              "start_index": 3258,
              "title": "THZ531 | CDK12/13 inhibitor | Axon 3402 | Axon Medchem",
              "url": "https://www.axonmedchem.com/3402-thz531"
            },
            {
              "type": "url_citation",
              "end_index": 3406,
              "start_index": 3346,
              "title": "THZ531 | CDK12/13 inhibitor | Axon 3402 | Axon Medchem",
              "url": "https://www.axonmedchem.com/3402-thz531"
            },
            {
              "type": "url_citation",
              "end_index": 3657,
              "start_index": 3594,
              "title": "LL-K12-18 | CDK12-DDB1enhancer,Cyclin K degrader | Axon 4281 | Axon Medchem",
              "url": "https://www.axonmedchem.com/4281-ll-k12-18"
            },
            {
              "type": "url_citation",
              "end_index": 3859,
              "start_index": 3796,
              "title": "LL-K12-18 | CDK12-DDB1enhancer,Cyclin K degrader | Axon 4281 | Axon Medchem",
              "url": "https://www.axonmedchem.com/4281-ll-k12-18"
            },
            {
              "type": "url_citation",
              "end_index": 4469,
              "start_index": 4298,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 4682,
              "start_index": 4511,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 4909,
              "start_index": 4738,
              "title": "Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) :: Carrick Therapeutics, Inc.",
              "url": "https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase"
            },
            {
              "type": "url_citation",
              "end_index": 5258,
              "start_index": 5160,
              "title": "CareAcross",
              "url": "https://www.careacross.com/clinical-trials/trial/NCT06600789?utm_source=openai"
            },
            {
              "type": "url_citation",
              "end_index": 5406,
              "start_index": 5326,
              "title": "CareAcross",
              "url": "https://www.careacross.com/clinical-trials/trial/NCT06600789"
            },
            {
              "type": "url_citation",
              "end_index": 5540,
              "start_index": 5442,
              "title": "CareAcross",
              "url": "https://www.careacross.com/clinical-trials/trial/NCT06600789?utm_source=openai"
            }
          ],
          "logprobs": [],
          "text": "- **Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer (PubMed)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/31668947/`\n  - Direct quotes:\n    - “Here we report the development of **SR-4835**, a highly selective dual inhibitor of **CDK12** and **CDK13**, which disables **triple-negative breast cancer (TNBC)** cells.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/31668947/))\n\n- **Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13 (PubMed)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/35938508/`\n  - Direct quotes:\n    - “dual **CDK12/13** degraders by employing the **proteolysis-targeting chimera (PROTAC)** technology.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35938508/))\n    - “The optimal compound **7f** effectively degraded **CDK12** and **CDK13**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35938508/))\n    - “**7f** markedly inhibited proliferation of multiple **TNBC** cell lines” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/35938508/))\n\n- **Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor (PubMed)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/34864331/`\n  - Direct quotes:\n    - “we have synthesized a potent **PROTAC** degrader **PP-C8** based on the noncovalent dual inhibitors of **CDK12/13**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))\n    - “**PP-C8** demonstrates profound synergistic antiproliferative effects with **PARP inhibitor** in **triple-negative breast cancer (TNBC)**.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/34864331/))\n\n- **Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (PubMed)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/32804079/`\n  - Direct quotes:\n    - “we report a new molecular glue **HQ461** discovered by high-throughput screening.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32804079/))\n    - “**HQ461** acts by promoting an interaction between **CDK12** and **DDB1-CUL4-RBX1** E3 ubiquitin ligase” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32804079/))\n    - “A provisional patent application (**PCT/CN2020/095482**) has been filed for the application of **HQ461**” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/32804079/))\n\n- **Dual-site molecular glues for enhancing protein-protein interactions of the CDK12-DDB1 complex (PubMed)**\n  - URL: `https://pubmed.ncbi.nlm.nih.gov/39090085/`\n  - Direct quotes:\n    - “This exploration leads to the creation of **LL-K12-18**, a dual-site molecular glue” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39090085/))\n    - “potency improvements in **MDA-MB-231** (88-fold) and **MDA-MB-468** cells (307-fold) when compared to its precursor compound **SR-4835**.” ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/39090085/))\n\n- **THZ531 | CDK12/13 inhibitor | Axon 3402 | Axon Medchem**\n  - URL: `https://www.axonmedchem.com/3402-thz531`\n  - Direct quotes:\n    - “**THZ531** is a first-in-class, potent, selective, covalent inhibitor of **CDK12** and **CDK13** with IC50 values of 158 nM and 69 nM, respectively.” ([axonmedchem.com](https://www.axonmedchem.com/3402-thz531))\n    - “CAS:  1702809-17-3” ([axonmedchem.com](https://www.axonmedchem.com/3402-thz531))\n\n- **LL-K12-18 | CDK12-DDB1enhancer,Cyclin K degrader | Axon 4281 | Axon Medchem**\n  - URL: `https://www.axonmedchem.com/4281-ll-k12-18`\n  - Direct quotes:\n    - “**CAS:  3081311-94-3**” ([axonmedchem.com](https://www.axonmedchem.com/4281-ll-k12-18))\n    - “The dual-site molecular glue **LL-K12-18** is an enhancer of **CDK12-DDB1** protein interaction and a potent degrader of cyclin K” ([axonmedchem.com](https://www.axonmedchem.com/4281-ll-k12-18))\n\n- **Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT7439 (CDK12/13 Inhibitor) (Carrick Therapeutics press release)**\n  - URL: `https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase`\n  - Direct quotes:\n    - “**CT7439**, a novel cyclin dependent kinase 12/13 (**CDK12/13**) inhibitor / **Cyclin-K glue-degrader**.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))\n    - “under study ID: **NCT06600789**.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))\n    - “including ovarian, breast and Ewing's Sarcoma.” ([carricktherapeutics.com](https://www.carricktherapeutics.com/investors/news-events/press-releases/detail/25/carrick-therapeutics-announces-first-patient-dosed-in-phase))\n\n- **A Modular Phase 1/2 Study with CT7439 in Participants with Solid Malignancies (CareAcross; trial listing w/ locations)**\n  - URL: `https://www.careacross.com/clinical-trials/trial/NCT06600789`\n  - Direct quotes:\n    - “NCT ID:  **NCT06600789**” ([careacross.com](https://www.careacross.com/clinical-trials/trial/NCT06600789?utm_source=openai))\n    - “Intervention name:  **CT7439 Capsules (0.5 mg, 1mg, 3mg)**” ([careacross.com](https://www.careacross.com/clinical-trials/trial/NCT06600789))\n    - “Country: **United States**” ([careacross.com](https://www.careacross.com/clinical-trials/trial/NCT06600789?utm_source=openai))"
        }
      ],
      "role": "assistant"
    }
  ],
  "parallel_tool_calls": true,
  "previous_response_id": null,
  "prompt_cache_key": null,
  "prompt_cache_retention": null,
  "reasoning": {
    "effort": "medium",
    "summary": null
  },
  "safety_identifier": null,
  "service_tier": "default",
  "store": true,
  "temperature": 1.0,
  "text": {
    "format": {
      "type": "text"
    },
    "verbosity": "medium"
  },
  "tool_choice": "auto",
  "tools": [
    {
      "type": "web_search",
      "filters": null,
      "search_context_size": "medium",
      "user_location": {
        "type": "approximate",
        "city": null,
        "country": "US",
        "region": null,
        "timezone": null
      }
    }
  ],
  "top_logprobs": 0,
  "top_p": 0.98,
  "truncation": "disabled",
  "usage": {
    "input_tokens": 63383,
    "input_tokens_details": {
      "cached_tokens": 4352
    },
    "output_tokens": 7419,
    "output_tokens_details": {
      "reasoning_tokens": 5968
    },
    "total_tokens": 70802
  },
  "user": null,
  "metadata": {}
}